Relacorilant Effectively Manages Cortisol Effects in Cushing’s Patients, Interim Phase 2 Data Show
News
Relacorilant, an investigational therapy developed by Corcept Therapeutics, may effectively manage the effects of excess cortisol in patients with Cushing’s syndrome, interim data from an ongoing Phase 2 trial show. ... Read more